Comparative Pharmacology
Head-to-head clinical analysis: AMITID versus TRIMIPRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITID versus TRIMIPRAMINE MALEATE.
AMITID vs TRIMIPRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.
Inhibits reuptake of norepinephrine and serotonin, with moderate anticholinergic, sedative, and antihistaminergic effects.
75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.
25-150 mg orally once daily at bedtime, starting at 25 mg and titrating up by 25 mg every 3-4 days.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; clinically, steady-state is reached within 2-3 days.
Terminal elimination half-life: 22–32 hours (mean 24 hours); in elderly or hepatic impairment, may extend to 40–50 hours requiring dose adjustment.
Renal: 60-80% as metabolites, <5% unchanged; Biliary/Fecal: 20-30% as metabolites.
Renal: ~70% as metabolites (unchanged <5%); fecal: ~30% via biliary excretion.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant